Ghrelin reduces rat myocardial calcification induced by nicotine and vitamin D3 in vivo

FEI WANG1,2, TAO JIANG1, CHAOSHU TANG3, ZIJIE SU1, NONG ZHANG1 and GUIZHONG LI2

1Department of Pathology, Shanghai Medical College, Fudan University, Shanghai 200032; 2Department of Pathophysiology, Ningxia Medical University, Yinchuan 750004; 3Department of Physiology and Pathophysiology, Peking University Health Science Center, Beijing 100069, P.R. China

Received April 1, 2011; Accepted May 6, 2011
DOI: 10.3892/ijmm.2011.710

Abstract. Ghrelin, a newly discovered bioactive peptide, initially was identified as a strong stimulant for the release of growth hormone (GH) and has improved cardiac function in patients suffering from end-stage chronic heart failure. Increasing evidence has demonstrated that ghrelin may have myocardial protective effects. However, the role of ghrelin in the pathogenesis of cardiovascular diseases remains unclear. In this study, an in vivo model of rat myocardial calcification induced by vitamin D3 and nicotine was used to study the possible mechanism in the regulatory action of ghrelin on the calcified myocardium. Calcification increased total Ca²⁺ content and ⁴⁵Ca²⁺ deposition in the myocardium and alkaline phosphatase (ALP) activation in the plasma. Compared with the control group, ghrelin mRNA expression was up-regulated and the myocardium calcium content was significantly increased in vitamin D3 and nicotine-treated rats. Rats treated with both low- and high-dose ghrelin decreased total Ca²⁺ content and ⁴⁵Ca²⁺ deposition in cardiac muscle and inhibited ALP activation in the myocardium and plasma, in a concentration-dependent manner. In addition, osteopontin (OPN) mRNA expression significantly decreased and that of endothelin (ET-1) significantly increased with myocardial calcification. Ghrelin treatment increased OPN expression at the mRNA level and reduced ET-1 mRNA expression in a dose-dependent manner. These results indicate that exogenous administration with ghrelin attenuates myocardial calcification induced by nicotine and vitamin D3, and that the possible mechanism is via the ghrelin-induced increase in the OPN mRNA levels and decrease in the ET-1 mRNA expression in the myocardium.

Introduction

Cardiovascular calcification is a common finding in many cardiovascular diseases, such as hypertension, atherosclerosis, diabetes mellitus, chronic renal failure, aging, aortic stenosis, and prosthetic valve replacements, which is believed to be an important risk factor of cardiovascular diseases (1). Cardiovascular calcification decreases cardio- and vasodilatation, increases stiffness and promotes formation of thrombus and rupture of atherosclerotic plaques. However, the mechanism by which calcification induces cardiovascular dysfunction and remodeling remains unclear. Calcification was once considered a passive deposition of calcium and phosphorus in the extracellular matrix and in cells. Recent studies point out that cardiovascular calcification is an active, regulated process, similar to osteogenesis and osteoporosis (2). During the development of vascular calcification, vascular cells including vascular smooth muscle cells (VSMCs), pericytes, fibroblasts and macrophages, transform into an osteoblast-like phenotype, characterized by an increase in alkaline phosphatase (ALP) activity, matrix vesicle formation and overexpression of bone morphogenetic proteins (BMPs), including BMP-2 and bone matrix proteins, such as osteopontin (OPN), osteonectin, and osteocalcin (3-5).

We previously reported that adrenomedullin (ADM), C-type natriuretic peptide (CNP), and parathyroid hormone-related peptide (PTHrP) attenuated VSMCs calcification; however, ET and angiotensin II accelerated VSMCs calcification (6). Besides, calcified VSMCs is able to secrete ADM, resulting in elevated ADM mRNA levels in calcified cells (7). Exogenous administration of ADM inhibits rat vascular calcification by improving the vascular ADM/ADM receptor/cAMP pathway.
in vivo (8). These results show that cardiovascular bioactive peptides have important regulatory roles in cardiovascular calcification. Ghrelin, a 28 amino acid peptide, is a newly discovered hormone, produced principally in the stomach, and identified as the endogenous ligand for the growth hormone secretagogue receptor (GHSR) (9). Recently, ghrelin and its receptors were detected in cardiovascular tissues (10). It is thus possible that ghrelin may be acting directly on the heart and vasculature rather than it effects being mediated by growth hormone (GH) (11). As an important autocrine/paracrine factor, ghrelin has various cardiovascular effects, including inotropic action, vasodilatation, anti-apoptosis, and anti-inflammation (12-16), that indicate that ghrelin may maintain cardiovascular homeostasis.

Stimulation of GHSR has been showed to prevent cardiac damage after ischemia-reperfusion in hypophyssectomized rats (17-22). Moreover, administration of ghrelin improved left ventricular dysfunction and attenuated the development of cardiac cachexia in a heart failure and shock model (22,23). In our reports, we found that ghrelin inhibited 45Ca2+ accumulation in cultured VSMCs in a concentration range from 10-40 to 10-2 M. Therefore, we hypothesized that ghrelin, as a paracrine/autocrine factor of cardiac tissue, may have an effect on the myocardial calcification process. In this study we established a rat model of myocardial calcification with vitamin D3 and nicotine administration to assess the effects of ghrelin on rat myocardial calcification and study its mechanism of action.

Materials and methods

Animals and drugs. The Council on Animal Care at the Peking University approved this study protocol. Male Sprague Dawley (SD) rats weighing 150-180 g were supplied by the Animal Center, Health Science Center, Peking University. Vitamin D3, nicotine and ALP assay kits were purchased from Sigma-Aldrich (St. Louis, MO). 45CaCl2 was obtained from NEN Life Science Products, Inc. (Boston, MA). Other chemicals and reagents were of analytical grade. The specific primers for OPN, ET-1, ghrelin and β-actin were synthesized by SBS Co. (Beijing, China). Ghrelin and ET-1 RIA kits were kindly provided by Phoenix Co. (USA).

Rat cardiovascular calcification model. An in vivo cardiovascular calcification model was produced according to the previously described method with minor modifications (24). Two-month-old male SD rats were randomly divided into five groups: normocalcemic control, nicotine plus vitamin D3 (VDN+G1 group) and VDN plus ghrelin (VDN+G2 group), in addition to receiving VDN. All animals were maintained on normal rat chow in a 12:12 h light-dark cycle and were given water ad libitum. The rats were caged individually after the initial treatment. After the end of 4 weeks all rats were anesthetized with urethane (1 g/kg, i.p.) and sacrificed. Blood was collected into a tube pre-treated with EDTA-Na2 (1 mg/ml), aprotinin (500 kIU), and plasma was separated by centrifugation (1,600 g, 15 min). The hearts were harvested, weighed and stored at -70°C.

Measurement of calcium content in the myocardium. The 20 mg of ventricular myocardium was dissolved in HNO3, completely dried, and then diluted with a blank solution (27 mmol/l KCl, 27 µmol/l LaCl3). The calcium content was determined with an atomic absorption spectrophotometer at 422.7 nm (25).

von Kossa staining for calcification. The protocol for von Kossa calcium staining of rat myocardium has been previously described (26). Briefly, a segment of the myocardium was excised and fixed in 10% formalin. Tissue samples were dehydrated and embedded in paraffin, then cut into 6-µm sections. The slides were deparaffinized and dehydrated before incubation in 5% silver nitrate solution for 30 min in the sun, and then washed with a solution of 5% sodium thiosulfate for 2 min. Finally, slides were counterstained with safranine (red staining) and examined under a light microscope by two individuals blinded to the treatment conditions.

Measurement of ALP activity in the myocardium. A homogenate of ventricular myocardium was prepared by Polytron in homogenizing buffer (20 mmol/l HEPES, pH 7.4, containing 0.2% NP-40, and 20 mmol/l MgCl2). The supernatant was collected following centrifugation at 8,000 x g for 10 min. ALP activity was determined by mixing 200 mg protein sample (in 200 µl) with 1 ml reaction mixture (alkaline buffer, stock substrate solution 1:1) and incubated at 37°C for 30 min. The stock substrate solution was prepared by dissolving the contents of a 100 mg capsule of Sigma 104 phosphatase substrate in 25 ml of ddH2O. The reaction was stopped by addition of 20 ml of 1 mol/l NaOH, and the absorbance at 405 nm was determined. The ALP activity was calculated using p-nitrophenol as a standard. One unit was defined as the activity produced by 1 nmol of p-nitrophenol within 30 min (25).

45Ca2+ uptake measurement. To determine 45Ca2+ accumulation in heart tissues, 20 mg of ventricular myocardium was sliced by a slicer and placed in 1 ml Krebs-Henseleit (K-H) solution (in mmol/l: NaCl 118, KCl 4.7, CaCl2 1.3, KH2PO4 1.2, MgSO4 1.2, NaHCO3 and glucose 11, pH 7.4), then, 37 kBq/ml of 45CaCl2 were added. After 8 h incubation, the reaction was stopped by addition of ice-cold 0.2 mol/l phosphate-buffer solution (pH 7.4). The tissue was dissolved with 88% formic acid at 80°C for 4 h. 45Ca2+-radioactivity was measured by a β-scintillation counter (Beckman LS 6500) (25).

Radioimmunoassay of endothelin and ghrelin levels in plasma. The acidulated plasma was applied to a Sep-Pak C18 cartridge (Millipore-Waters, Milford, MA, USA). After washing the cartridge with 10 CH3CN in 0.1% trifluoroacetic acid, the absorbed materials were eluted with 50% CH3CN in 0.1% trifluoroacetic acid, lyophilized and stored at -70°C until assayed. Endothelin and ghrelin levels in the plasma were
measured using a specific radioimmunoassay (RIA) kit for ET and ghrelin, respectively (27). Rabbit polyclonal anti-ET and anti-ghrelin were used for RIA in these kits. The IC\textsubscript{50} for rat ET was 14.6 pg/tube. The cross-reactivity with rat ET was 100%, and that with ET-2, ET-3 and angiotensin II was 3.5, 28 and 0%, respectively. The IC\textsubscript{50} for rat ghrelin was 6.9 pmol/tube, and binding was 35% in this assay. There was 100% cross-reactivity with rat and human ghrelin. All assays included 12 plasma control samples from common stock solutions, which were frozen in aliquots at the beginning of the study, in order to normalize each test for inter-assay variability. Based on these controls, the intraassay coefficient of variation was 8.7% and the interassay coefficient of variation was 14.6% (n=10). No cross-reactivity was seen with leptin, orexin A and B, neuropeptide Y, galanin or vasoactive intestinal polypeptide, assessed with doubling dilutions from 100 to 1 ng/ml.

RT-PCR for OPN, endothelin and ghrelin mRNA. Total-RNA from myocardium was extracted with TRIzol (Gibco-BRL, Rockville, MD) reagent (28). RT-PCR was performed in a total volume of 25 µl. The PCR products were separated on a 1.5% agarose gel, and stained with ethidium bromide. The ratio of optical densities of OPN, ET and ghrelin mRNA to \( \beta \)-actin were measured using the Gel Documentation System (Bio-Rad, Hercules, CA). Oligonucleotides were synthesized by Sai Baisheng Biotechnology (Beijing, China). The sequences of the oligonucleotide primers were as follows: ghrelin-S, 5'-TTGAGCCCAGACCCAGAA-3'; ghrelin-A, 5'-AGTGGAGGGCAGGAGCAGCT-3'; OPN-S, 5'-CTCGCGGTTGAAAGTGGCTGA-3'; OPN-A, 3'-GACCTCAGAAGATGAACCTCT-5'; ET-S, 5'-GGTCTTGATGCTGTGCTGA-3'; ET-A, 5'-GAGCTGAGGAGGAGGTGCGA-3', as well as \( \beta \)-actin-S, 5'-ATCTGGCACCACACCTCT-3'; and \( \beta \)-actin-A, 5'-AGCCAGGTCCAGACGCA-3' for calibration of sample loading. Other chemicals and reagents were of analytical grade.

Statistical analysis. Data were expressed as mean ± SEM. One-way ANOVA followed by the Student Newman-Keuls test were performed. A two-tailed P<0.05 was considered statistically significant.

Results

Calcium deposits in the myocardium. Control myocardium showed no calcified deposits (Fig. 1A and E), but calcified myocardium showed strong positive staining among the myocardial matrix (Fig. 1B and F). After ghrelin treatment of 1 (Fig. 1C and G) or 10 nmol/kg/day (Fig. 1D and H) for 4 weeks, the positive staining in the myocardial matrix was decreased compared to that in the calcified myocardium. The data indicate that ghrelin reduces the deposition of calcium within the myocardial matrix.

Ghrelin reduces the myocardial calcium content induced by VDN. Nicotine and vitamin D3 (VDN) are potent agents used in calcification models to induce \( \text{Ca}^{2+} \) accumulation in the myocardium and vascular tissues (24). As shown in Fig. 2, the myocardium calcium content was significantly increased (129%, P<0.01) in the VDN group compared with the control group. Treatment of rats with ghrelin significantly decreased myocardium calcium contents. The myocardial calcium contents
were decreased by 13% (P<0.01) and 28% (P<0.01) in rats treated with 1 and 10 nmol/kg/day of ghrelin, respectively, in comparison to the VDN alone group. The calcium content in the VDN+G2 group was lower than that in the VDN+G1 group (P<0.01).

Ghrelin inhibits ALP activity activated by VDN in the plasma and myocardium. ALP is a specific enzyme that promotes calcium deposition in tissues. Administration to rats with VDN significantly increased ALP activity in the myocardium, to levels that were 65% higher than those in the control group (P<0.01). However, ghrelin administration to VDN-treated rats significantly inhibited ALP activation in the myocardium. The inhibition rates were 18 and 27%, respectively, in the VDN+G1 and VDN+G2 groups, compared with the VDN alone group (P<0.01) (Fig. 3A). In physiological conditions, ALP mainly exists in the cytoplasm. It will leak out into the blood plasma when cells are injured. The plasma ALP activity was significantly increased in the VDN group in comparison to the control (P<0.01) (Fig. 3B). However, the plasma ALP activity was obviously reduced in the ghrelin-treated groups compared with the VDN alone group (P<0.01). Both in the myocardium and plasma, ALP activity was lower in the VDN+G1 than in the VDN+G2 group (P<0.01).

Ghrelin reduces calcium accumulation in the myocardium induced by VDN. As shown in our experiments, the myocardial $[^{45}\text{Ca}^2+]$ uptake was 2.7-fold higher in rats treated with VDN alone than in controls (P<0.01, Fig. 4). However, administration with ghrelin significantly attenuated myocardial $[^{45}\text{Ca}^2+]$ uptake by 44% in the VDN+G1 and by 46% in the VDN+G2 groups, respectively, compared with the VDN alone group (P<0.01) (Fig. 4).

Ghrelin up-regulates myocardial OPN mRNA levels. OPN is a regulatory protein for tissue calcium deposition. OPN mRNA levels in the myocardium were down-regulated in the VDN group (Fig. 5). However, OPN mRNA levels were up-regulated after treatment with ghrelin 1 and 10 nmol/kg/day, and were increased by 89 and 96% respectively that in VDN alone group (all P<0.01).

Effects of ghrelin on ghrelin and ET-1 levels in the myocardium and plasma. As shown in Fig. 6, ET-1 mRNA levels in the myocardium were 17% higher in the VDN group than in the control group (P<0.05). Interestingly, rats treated with ghrelin...
significantly down-regulated ET-1 mRNA expression in the myocardium. ET-1 mRNA levels in the myocardium were 17% higher in the VDN group than in the control (Con) group (P<0.05). The ET-1 mRNA levels were decreased by 61% in the VDN+G1 group and by 78% in the VDN+G2 group compared with the VDN alone group (all P<0.01). G1, G2, 1 and 10 ng/kg/day ghrelin.

Discussion

It is universally considered that vascular calcification is a severe risk factor. Recently, growing evidence shows that tissue calcification during cardiovascular diseases occurs not only in the vascular vessels and cardiac valves but also in the myocardium, especially during end-stage renal disease (2).

Calcium crystals deposit extensively on the heart muscle, and calcium overload occurs in the myocardial cells. Calcium accumulation in the myocardium has a deleterious effect on cardiac performance (2,29). Rostand and colleagues found myocardial calcification with a reduction in myocardial performance and even heart failure in patients undergoing dialysis (3). However, the mechanism of cardiac dysfunction during myocardial calcification is unknown. Cardiovascular calcification is not a 'passive' crystallization process, but a biologically active one (2). It is considered an actively regulated process similar to osteogenesis and osteoporosis (30). Calcified cells with an osteoblast-like cell phenotype traits are the cellular basis of calcification pathogenesis (31). When matrix vesicles appear in the cells, they synthesize large amounts of bone matrix protein and ALP, causing calcium deposit in cells and extracellular matrix. Growing evidence indicates that cardiovascular bioactive peptides are involved in regulating cardiovascular calcification, such as angiotensin II (32), platelet-derived growth factor (33), CNP, PTHrP, ET-1 and adrenomedulin (6). Ghrelin, a recently discovered 28 amino acid peptide, has received considerable attention for its effects on food intake and adiposity, in addition to its GH-releasing properties (34). Putative receptors for ghrelin have been identified in blood vessels and cardiomyocytes, suggesting that the peptide could play a modulatory role in cardiovascular function (18).
The administration of VDN induces calcium overload in arteries, media calcification, and, finally, widespread cardiovascular calcification (24). We used VDN to investigate myocardial calcification in rats. After 4 weeks of treatment, calcium contents, Ca\(^{2+}\) accumulation, and ALP activity in the myocardium increased significantly, in accordance with the results of previous research (24). Interestingly, all three of these parameters were significantly inhibited by ghrelin administration, suggesting that ghrelin exerts protective effects on myocardial calcification induced by VDN.

The underlying mechanisms of the ghrelin-induced inhibition of myocardial calcification remain unclear. Growing evidence suggests that cardiovascular calcification is a biologically regulated phenomenon and may be subject to prevention and reversal (2). The calcified cells synthesize and secrete major components of bone osteoid, such as ALP, BMP-2, OPN. OPN and matrix \(\gamma\)-carboxylated glutamate protein (MGP), which may regulate the amount of calcium deposited in the cardiovascular tissues (3). Our results indicate that VDN significantly inhibits OPN mRNA expression in the myocardium. Administration of ghrelin markedly induced OPN mRNA expression which was accompanied with a reduction of myocardial calcium content and Ca\(^{2+}\) accumulation, suggesting that the beneficial effects of ghrelin on myocardial calcification were related to the stimulation of OPN expression. OPN is a non-collagenous, glycosylated phosphoprotein associated with biomineralization in osseous tissues, as well as ectopic calcification. Jono and Giachelli (35) reported that OPN is co-localized with calcified deposits in atherosclerotic lesions, and that OPN potently inhibited calcium deposition in a human smooth muscle cell (HSMC) culture model of vascular calcification. They further report that the ability of OPN to inhibit calcification completely depends on post-translational modifications, since bacteria-derived recombinant OPN did not inhibit HSMC mineralization. Phosphorylated OPN (P-OPN) dose-dependently inhibited calcification of HSMC cultured in vitro, while none of the non-phosphorylated OPN fragments affected calcification. P-OPN was treated with ALP to create dephosphorylated OPN. Dephosphorylated OPN dose not have an inhibitory effect on calcification. The expression of OPN mRNA and P-OPN secretion by HSMC were decreased in a time-dependent manner during calcification of cultured cells.

The peptide ET-1 is a potent and long-lasting vasoconstrictor and mitogen. It was reported that ghrelin (0.1-300 nmol/l) potently dilated human arteries constricted by 10 nmol/l ET-1, indicating that ghrelin is an effective and natural para/autocrine factor regulating cardiovascular calcification. Our data suggest that ghrelin may be an important para/autocrine factor regulating cardiovascular calcification. The beneficial effects of ghrelin on the cardiovascular system will be a new target for preventing cardiovascular diseases, such as cardiovascular calcification and heart failure.

References